Innodem Neurosciences

Innodem Neurosciences collaborates with the pharmaceutical industry, leading healthcare professionals, and artificial intelligence experts to develop and promote eye movement biomarkers (EMB) and gaze mapping biomarkers (GMB) as crucial clinical assessment tools in the field of neurology. It constructs a series of disease-specific tests, integrated into an intuitive application capable of capturing EMB and GMB data. The vision is that, over time, by leveraging the latest advancements in machine and deep learning, this EMB/GMB platform will assist users in accurately diagnosing and monitoring neurological disorders affecting eye movement or cognition, such as multiple sclerosis, Alzheimer's disease, Parkinson's disease or related conditions, frontotemporal dementia, cancer-related cognitive impairment (Chemo Brain), and many other diseases.